ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,308.12
0.76%
US Tech 100
18,357.20
1.16%
다우존스 지수
39,116.35
0.13%
Bitcoin
69,080.18
1.70%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Edgewise Therapeutics Inc (EWTX)

  7. Edgewise Therapeutics Inc (EWTX) 뉴스

EWTX

Edgewise Therapeutics (EWTX)

Edgewise Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:EWTX
일자시간출처헤드라인심볼기업
2024/05/1022:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/1022:07Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/1021:00Business WireEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0922:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0921:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0921:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0921:00Business WireEdgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0722:16Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0722:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0721:00Business WireEdgewise Therapeutics Appoints Arlene Morris to its Board of DirectorsNASDAQ:EWTXEdgewise Therapeutics Inc
2024/05/0621:00Business WireEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)NASDAQ:EWTXEdgewise Therapeutics Inc
2024/04/2321:00Business WireEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesNASDAQ:EWTXEdgewise Therapeutics Inc
2024/04/1605:05Business WireEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)NASDAQ:EWTXEdgewise Therapeutics Inc
2024/03/2821:00Business WireEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionNASDAQ:EWTXEdgewise Therapeutics Inc
2024/03/2721:00Business WireEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
2024/03/0522:00Business WireEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2822:00Business WireEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/2222:00Business WireEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/1422:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/1322:00Business WireEdgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)NASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/1007:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
2024/02/0806:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/2006:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1922:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1922:37Business WireEdgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common StockNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1920:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
2024/01/1920:04Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:EWTXEdgewise Therapeutics Inc
 검색 관련기사 보기:NASDAQ:EWTX

최근 히스토리

EU
I383T
I383T
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유